Drug Profile
BIO 024
Alternative Names: BIO024Latest Information Update: 26 Aug 2015
Price :
$50
*
At a glance
- Originator Gardant Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alopecia
Most Recent Events
- 04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
- 22 Oct 2005 Phase-II clinical trials in Alopecia in USA (Topical)